The Food and Drug Administration granted an emergency use authorization for the booster in individuals age 65 years old and older, and individuals age 18 to 64 years old within certain high-risk groups.
Rani has agreed to evaluate BFI-751 in its RaniPill capsule, a novel, proprietary and patented platform technology intended to replace subcutaneous or IV injection of biologics with oral dosing.
The organizations’ Pharmacy Access Initiative will generate real-time information for various officials, academics and industry leaders to identify communities that lack pharmacy access.
